• Aptamer-based COVID-19 diagnostics

Aptamer Group advances COVID-19 testing capabilities with Integumen

Aptamer Group Ltd, the developer of diagnostic and therapeutic aptamer reagents, is pleased to announce further progress in their collaboration with Integumen plc (AIM: SKIN) to develop Microtox PD, a wastewater detection system for COVID-19. Aptamer Group is also collaborating with Integumen on the development of a new personalised rapid COVID-19 breath test, Microtx BT, […]

Integumen signs MTA with Aptamer Group Ltd

Collaboration to use aptamers in a device to detect SARS-CoV-2 in wastewater
Aptamer Group, developers of Aptamer reagents, is pleased to announce that it has signed a Material Transfer Agreement (“MTA”) with the Integumen. This recently established collaboration is to use  Aptamers in a device to detect SARS-CoV-2 in wastewater. Once ready, the Aptamers will play […]

Aptamer Group and Cytiva form new collaboration for the development of COVID-19 Rapid Test

Collaboration to produce a rapid test for the COVID-19 coronavirus infection
Aptamer Group, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The company will use its recently developed aptamer reagent combined with Cytiva’s lateral flow technology to produce a Lateral Flow Device (LFD)*. Aptamer […]

Aptamer Group making headlines on their Point of Care COVID19 reagent developments

 
Arron Tolley, CEO of Aptamer Group discusses the teams progress on COVID19 tests:
 

https://www.linkedin.com/feed/update/urn:li:activity:6678971478534324225

 

Aptamers in the battle against COVID19

#covid19 #inthistogether #covid19test #covid19uk #covidtesting #coviduk #covidUSA #covidUS #covidoutbreak #covidresearch #aptamer #diagnostics #immunoassay #lateralflow #theteam #keyworkers #healthcareheroes #biotech #immunology #moleculardiagnostics #precisionmedicine #aptamergroup #pharmaceutical #pharma #medicine #productmarketing #medicaldevices #drugdiscovery #biomarkers #drugdevelopment #digitalhealth #biopharma #biotechnology #aptamers
  • Aptamer-based COVID-19 diagnostics

COVID-19 Reagents

COVID-19 Reagents We invite development partners to join us in this endeavour

Aptamer Group and Valitacell announce partnership to build new drug discovery platform

Biotechnology companies Aptamer Group and Valitacell Ltd have joined forces to develop a next-generation screening platform for drug development.
Aptamer Group will be working alongside Valitacell to engineer the platform, in which aptamers – short sequences of DNA or RNA – are used in Valitacell’s high throughput screening processes. These screening processes can rapidly identify promising […]

Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme

30th April 2019
Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester and Cancer Research UK. The project will explore the potential of aptamers as […]

Aptamer Group March 2019

31st March 2019
This month:

Novel ELISA like assay for small molecules
Moxifloxacin aptamer and intellectual property (IP) availability
Interesting applications in biologic and biosimilar analysis and cell imaging

With lots of exciting new data ongoing for multiple applications in the commercial and academic space, Aptamer Group would like to share with you information that may be […]

  • Working in a lab at Aptamer Group

Aptamer Group January 2019

17th January 2019
This month:

Aptamer Group announces collaboration with AstraZeneca
Cancer Biomarker Capture and Elution by Cell Specific Aptamers
Laboratory and Office expansion
Interesting applications in glioblastoma and hepatocellular carcinoma (HCC) biomarker aptamers

With lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to share with […]